To systematically review the current evidence examining restless legs syndrome (RLS) and periodic limb movements in sleep (PLMS) as prognostic factors for all-cause mortality and incident cardiovascular events (CVE) in longitudinal studies published in the adult population. Methods: All English language studies (from 1947 to 2016) found through Medline and Embase, as well as bibliographies of identified articles, were considered eligible. Quality was evaluated using published guidelines. Results: Among 18 cohorts (reported in 13 manuscripts), 15 evaluated the association between RLS and incident CVE and/or all-cause mortality and 3 between PLMS and CVE and mortality. The follow-up periods ranged from 2 to 20 years. A significant relationship between RLS and CVE was reported in four cohorts with a greater risk suggested for severe RLS with longer duration and secondary forms of RLS. Although a significant association between RLS and all-cause mortality was reported in three cohorts, a meta-analysis we conducted of the four studies of highest quality found no association (pooled hazard ratio = 1.09, 95% confidence interval: 0.80-1.78). A positive association between PLMS and CVE and/or mortality was demonstrated in all included studies with a greater risk attributed to PLMS with arousals.
INTRODUCTION
Restless legs syndrome (RLS) is a common but under-recognized chronic sensorimotor disorder characterized by a strong, nearly irresistible urge to move the limbs which is usually worse at rest, occurs in the evening or night time, and is relieved with movement.
1-3 RLS symptoms may range from being minimally annoying to severely disruptive of life. The prevalence of RLS in the general population has been reported to be between 5% and 10% [4] [5] [6] [7] and is estimated to be 2.7% for those with moderately or severely distressing symptoms. 4 Periodic limb movements in sleep (PLMS) are characterized by periodic episodes of repetitive limb movements during sleep, which most often occur in the lower extremities and may be associated with arousals from sleep. PLMS are seen in about 80-90% of patients with RLS, but are also commonly observed with increasing age and in other disorders, and are not specific for RLS. 8 The overall prevalence of PLMS in the general population (defined as a periodic limb movement index > 15/hour) has been reported to be between 4.3% and 9.3%. 9 Despite sharing some common underlying pathophysiological mechanisms with sleep-disordered breathing, which has been shown to be closely associated with cardiovascular (CV) consequences, 10 the prognostic implications of RLS and PLMS have been relatively underexplored in the context of CV and cerebrovascular disease. Multiple mechanisms may modulate an association between RLS/PLMS and CV and cerebrovascular disease including inflammation, 11 24 United States Wisconsin Sleep Cohort RLS: "repeated urge to move your legs" and "strange and uncomfortable feelings in the legs," "when sitting or lying down" which occur at least weekly, "get better when you get up and start walking" and "disrupt your sleep". 
Information Sources and Data Searches
All peer-reviewed studies published in the English language from 1947 to July 2016 that used a longitudinal study design and collected data in either a prospective or retrospective manner were eligible. Articles were identified using Medline and EMBASE, and the bibliographies of identified articles and reviews were also reviewed. We developed a comprehensive search strategy to identify prognostic studies of RLS/ PLMS that examined the outcomes of CVE and mortality. 39 The medical subject headings (MeSH) used for our literature search to identify the exposures of interest were "Restless Legs Syndrome" and "Nocturnal Myoclonus Syndrome." 40 The keywords were: "restless legs syndrome," "Ekbom syndrome," "Willis-Ekbom disease," "periodic limb movement disorder," "PLMD," "sleep-related movement disorder(s)," "leg motor activity," "myoclonic hyperkinesias," "nocturnal myoclonus syndrome," "RLS," "periodic leg movement(s)," "periodic limb movement(s)," "sleep leg movement(s)," and "PLM," 40 The full search strategy for MEDLINE is available in a data supplement (Supplementary Table S1 ). The search terms were adapted for use with other bibliographic databases. The initial searches were rerun just before the final analyses to retrieve further studies for inclusion.
Inclusion and Exclusion Criteria
We included studies that met the following criteria: (1) Evaluated adults (ie, patients ≥18 years of age); (2) PLMS were detected using polysomnography (PSG), and/or RLS was diagnosed using any recognized diagnostic criteria at baseline; (3) included only primary or both primary and secondary forms of RLS; (4) reported the proportion of participants without RLS/PLMS; and (5) followed patients for at least 1 year. We excluded studies that (1) evaluated adolescents or children (ie, patients < 18 years of age), (2) only reported on secondary forms of RLS, and those that (3) examined PLMS that were associated with a particular disease (eg, heart failure or renal disease). Although there is no sufficient evidence to support well-defined subtypes of RLS, we referred to "primary" forms of RLS when the cause was not definitively known and to "secondary" RLS when the condition occurred in association with a particular disease known to be strongly associated with RLS (eg, iron deficiency, pregnancy, or chronic renal failure). 3, 41 We excluded studies that examined only secondary forms of RLS because such presentations may be a manifestation of an underlying condition and reflect its severity and may also have a different pathogenesis compared to primary RLS and require different management strategies. For the same reasons, we excluded PLMS that were associated with a particular disease.
Our predictors were the presence and severity (if available) of RLS or PLMS. The adverse outcomes evaluated (either objectively documented or self-reported) were (1) CVE (nonfatal and fatal) and (2) all-cause mortality. CVE included coronary artery disease (eg, angina, myocardial infarction, and coronary revascularization procedures), stroke, congestive heart failure, and arrhythmias.
Data Extraction: Selection and Coding
Two reviewers (TK, MK) independently screened study titles and/or abstracts and read the full texts of manuscripts that appeared to fulfill the inclusion criteria. Discrepancies in opinion were resolved through discussion with a third reviewer (MIB).
A previously developed standardized form 10 was used to assess study quality and synthesize study results from the included articles. Extracted information included the following: (1) study design (eg, prospective or retrospective); (2) study setting (eg, clinical vs. community-based study); (3) demographics of the study population and baseline characteristics; (4) details of the definition(s) of RLS/PLMS; (5) recruitment and study completion/attrition rates; (6) definition of outcomes and timing of measurements; (7) the analytic approach used; (8) 42, 43 The appraisal consisted of two steps: the first step involved assessment of six potential sources of bias (i.e., study participation, study attrition, prognostic factor and outcome measurements, study confounding, and statistical analysis and reporting); the second step involved grading the presence of potential biases as "Yes," "Partly," "No," or "Unsure". A similar approach to the Scottish Intercollegiate Guidelines Network (SIGN) methodology (available from: http://www.sign.ac.uk/methodology/ checklists.html) was applied to summarize the overall level of potential bias for each study: (1) "++" when all or most of the quality criteria proposed by Hayden et al. were fulfilled (allowing one "Partly" while appraising all potential sources of bias); (2) "+" when some of the criteria were fulfilled; (3) "−" when few or no criteria were fulfilled (ie, at least one "Yes" for a potential form of bias). In addition, as proposed by SIGN, studies with a retrospective study design did not receive a "++" rating, as this study design is weaker than a prospective approach. In this manuscript, we refer to studies receiving an overall assessment of "++" as "high quality studies" and studies receiving an overall assessment of "+"as "moderate quality studies", as was used in a previously published prognostic review. 10 Details are presented in a data supplement (Supplementary Table S2 ).
Data Synthesis
The included studies were synthesized through tabulation and qualitative description. We anticipated that there would be limited scope for meta-analysis due to the high heterogeneity between studies. However, where studies used the same definition for RLS/PLMS, with the same outcome measure, we planned to pool adjusted hazard ratios (aHRs) with their 95% confidence intervals (CIs) extracted from each article using a random-effects (DerSimonian-Laird estimator for the amount of heterogeneity) meta-analysis in R, version 3.1.0 (www.r-project.org) using the "metafor" package. Heterogeneity was assessed using the Cochran's Q-test of (residual) heterogeneity; a p-value of less than .10 was considered to represent evidence of heterogeneity. 44 To quantify inconsistency, we used an I 2 statistic estimate (percent), which assesses how much of the total variability in the effect size estimates can be attributed to heterogeneity between studies. 45 We considered an I 2 value greater than 50% to be indicative of substantial heterogeneity. 46 If the necessary data were available, we planned to present the results separately for individuals with RLS and PLMS, as well as stratify separately for our outcomes of CVE and all-cause mortality.
RESULTS

Study Selection and Quality Assessment
Of the 52 manuscripts we identified, 13 articles were included 26, 47-58 ( Figure 1 ): ten assessed the association between RLS and CV events and/or mortality, and three assessed the association between PLMS and our outcomes of interest. Reasons for the exclusion of the 39 studies are presented in a data supplement (Supplementary Table S3 ). In total, 18 cohort studies were appraised for quality, since three manuscripts used data from more than one cohort study. Specifically, four prospective cohorts, the Dortmund Health Study (DHS), Study of Health in Pomerania (SHIP), Women's Health Study (WHS), and Physicians' Health Study (PHS) were used in multiple studies to address different outcomes: Szentkirályi et al. 50 , used data from all four cohort studies (outcome was mortality), Winter et al. 51 , from two cohort studies (WHS, PHS; CVE outcome), and Szentkirályi et al. 53 from two cohort studies (DHS, SHIP; CVE outcome). 36 Of the 18 cohort studies (Table 2 ), 17 were assessed as having "Partly" or "No" on all bias criteria. Eight of these cohorts, published in five manuscripts, were identified as being of high quality. 26, [50] [51] [52] 56 Study Characteristics Summaries of the included studies are presented in Table 3 . Of the 18 cohorts evaluated, eight (six with a prospective design) investigated the association between RLS and CV events, eight (seven with a prospective design) examined the link between RLS and all-cause mortality, and three (one with a prospective design) studied the association between PLMS and CV events or all-cause mortality.
The eight cohort studies that evaluated RLS as a prognostic factor for CV disease 48, 49, 51, [53] [54] [55] examined diverse middle-aged populations including community cohorts, health administrative data, registered nurses, physicians, and other health care professionals; the smallest sample size among these cohort studies was 1312 subjects. Two studies assessed only men 48, 51 and another two studies examined only women. 49, 51 Only two studies used the International Restless Legs Syndrome Study Group (IRLSSG) criteria to define RLS. 51, 53 The follow-up assessments ranged from 2.1 to 10 years and from 47 to 1064 CVE occurred including ischemic heart disease and stroke (both fatal and nonfatal) as defined using ICD-9 and ICD-10 codes, medical records, mailed questionnaires, and face-to-face interviews.
Eight cohort studies examined RLS as a prognostic factor for all-cause mortality. 26, 47, 50, 52, 55 All but one study examined middle-aged populations using health administrative data, population-based cohorts, and cohorts of health professionals; of these cohort studies, the smallest number of subjects included was 1299. Two cohorts evaluated only men 50, 52 and one study examined only women. 50 Five of the eight cohorts used the IRLSSG criteria to define RLS. The follow-up period ranged from 3.5 to 20 years, and across all studies from 55 to 2765 individuals died.
Three studies focused on PLMS, assessed by in-laboratory or in-home PSG, as a prognostic factor for CVE and/or allcause mortality. [56] [57] [58] These studies were based on middle-aged or elderly populations; the smallest number of subjects included among these studies was 584. One study was based on only men; two studies defined PLMS based on full PSG. During the median follow-up that ranged from 2.8 to 5.7 years, 90 to 1172 events occurred. CVE and mortality were defined based on ICD-9 and ICD-10 codes, patient medical records and supporting documentation, interviews with participants and next of kin, and death certificates.
Synthesis of Results
The evidence for an association between RLS and CVE was mixed and was based on eight study cohorts, two of high quality (published in one paper) 51 and six of moderate quality. 48, 49, [53] [54] [55] Four study cohorts supported a positive association, while another four did not support a significant relationship. Neither of the high quality study cohorts reported on by Winter et al. 51 found a significant association between RLS as defined by IRLSSG criteria and CV disease in either men or women (Table 3 ). Two of three cohort studies of moderate quality found an association between RLS and stroke. 48, 55 With regards to other CV outcomes, a positive association was only found for individuals who reported chronic RLS symptoms (≥3 years) 49 or secondary RLS 54 and in one study based on health administrative data. 55 The evidence for an association between RLS and all-cause mortality was based on eight study cohorts, five of high quality 26 ,50,52 and three of moderate quality. 47, 50, 55 Only three of the eight study cohorts demonstrated a significant relationship between RLS and all-cause mortality. We conducted a meta-analysis on the four cohorts of high quality that used the IRLSSG criteria to define RLS 50, 52 and also found that the association between RLS and all-cause mortality was not significant (pooled aHR = 1.09, 95% CI: 0.80-1.78, I 2 = 0%, p-value for the test for heterogeneity = .89) (Figure 2 ). In the one study of high quality which did not use the IRLSSG criteria, RLS was found to be a significant predictor only in women with daytime sleepiness. 26 The evidence for an association between PLMS and CVE and mortality was based on one study of moderate 58 and one study of high quality 56 ; both studies demonstrated a significant association between PLMS and our outcomes of interest. After adjusting for confounders, an increase in the frequency of PLMS in sleep, with or without related arousals, was associated with a 5-26% increased hazard for the composite CV outcome 56, 58 and a 5% increased risk of all-cause mortality. 58 The effect of a periodic limb movement arousal index ≥5 was comparable with that of a PLM index ≥30.
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DISCUSSION
We conducted a systematic review to investigate the relationship between RLS and PLMS with incident CVE and all-cause mortality. Of the 18 cohorts evaluated (reported in 13 manuscripts), 14 (78%) study cohorts used a prospective study design and eight (44%) were of high quality. Most of the included study cohorts investigated the association between RLS and CV events and/or all-cause mortality.
Overall, the evidence supporting RLS as a prognostic factor for incident CVE was mixed with neither of the two high quality study cohorts revealing a significant link. Individuals with secondary (but not primary) forms of RLS and longer term exposure to RLS appeared to be at higher risk of incident CVE. The association between RLS and all-cause mortality was not significant, as assessed by a meta-analysis we performed on the four studies of high quality that used the IRLSSG criteria to define RLS. 50, 52 Finally, the evidence supporting the role of PLMS as a prognostic factor for incident CVE and all-cause mortality was very limited 56, 58 ; however, the collective literature to date suggests a significant association, potentially stronger for PLMS associated with arousals.
Potential mechanisms that link RLS and CVE include sympathetic overactivity, hypoxia, and vascular risk factors (VRFs) frequently associated with RLS (eg, diabetes, hyperlipidemia, and obesity 15 ); however, given that the exact time of the incident CVE is unknown, CVE could alternatively lead to RLS via vascular pathology in the central nervous system or the periphery.
28,59,60
The inconsistent results among the studies evaluating RLS as a predictor for CVE and mortality are likely explained by several factors, including variability in the definitions and methods used to ascertain a diagnosis of RLS (as well as RLS severity), the absence of information on primary versus secondary forms of RLS in some studies, lack of information on the presence of PLMS at baseline and treatment of RLS in follow-up, variability in the demographic characteristics of the participants evaluated, differences in study attrition rates and follow-up times, and the relatively small number of events per outcome in some studies. The inconsistent and limited available evidence on the association between RLS and individual CV outcomes could mean there are few true relationships. The variety of definitions used for the components of the composite CV outcomes and the relatively small numbers of events per separate A participant who had symptoms ≥5 times per month and answered yes to the subsequent questions was considered to have RLS; others (including men with symptoms 1-4 times per month) were classified as no RLS. *p < .05. 47, 49, 56, 57 the relationship with CVE was observed to be weaker; this was likely because of the presence of various comorbid conditions that likely weakened any significant association seen with RLS.
Because some studies relied on self-report of symptoms via questionnaires, the possibility of having incorrectly categorized patients with RLS (rather than with a condition that mimics RLS symptoms) is a potential issue; prior work has demonstrated that the four core diagnostic criteria for RLS cannot exclude RLS from conditions that may present with similar sensory symptoms (eg, leg cramps, peripheral neuropathy, radiculopathy, arthritis, positional discomfort and so on). 61 Hence, some studies may have included patients with "RLS mimics" and contaminated the results. On the other hand, usage of "physician-diagnosed RLS" on questionnaires in other studies may have underestimated the true prevalence of this condition because physicians may underdiagnose RLS 4 ; in addition, use of "physician-diagnosed RLS" may have led to a selective identification of individuals with severe RLS. 49 Ideally, the presence of RLS would be determined via diagnostic interviews with participants conducted by physicians or other trained personnel; however, use of such a method would be impractical or costly for large studies. Most studies also used self-report measures of baseline comorbidities, which may be more vulnerable to misclassification as well.
The finding that secondary, but not primary, forms of RLS were linked with incident CVE 54 may be an important finding explained by the complex and incompletely understood pathogenesis of RLS. Important interactions between genetic factors and comorbid medical conditions may contribute to the pathogenesis of RLS. 62 One limitation of most of the epidemiological studies reviewed in the present manuscript is that they did not distinguish between primary and secondary forms of RLS. As proposed by Wong et al., 63 an explanation for the mixed results in the present literature could be that study cohorts negative for a significant relationship may have been enriched with primary RLS cases, while study cohorts demonstrating a positive link may have been enriched in secondary RLS cases. Secondary forms of RLS may have contributed to a greater risk for CVE through the RLS-associated conditions that gave rise to the RLS symptoms (eg, renal disease, iron deficiency, anemia, etc.). 63 The finding that women with RLS for at least 3 years had a higher risk of incident CVE suggested that longer term exposure to RLS-associated conditions may have contributed to the origin of vascular disease. 49 As recently proposed by Trenkwalder et al., 62 the traditional dichotomy between primary and secondary forms of RLS may be misleading. Rather, it has been suggested to view RLS as the complex interaction of genetic and environmental factors: the more genetic factors contribute to the manifestation of RLS, the fewer comorbid medical conditions are needed to develop the phenotype of RLS. 62 Although speculative and beyond the data presented in our review, primarily genetic manifestations of RLS may not be significant contributors to incident CVE, while manifestations of RLS mostly associated with comorbid conditions may be potentially important contributors to CVE, with more severe and longer duration exposures portending poorer outcomes.
Because observational studies cannot determine the direction of the relationship between RLS and CVE, the observed data are limited by unaddressed potentially confounding factors; there is also a possibility that the cerebrovascular and CVE themselves, or various VRFs, gave rise to the phenotype of RLS. It is well established that stroke can give rise to both RLS and PLMS. 59 In addition, RLS has been demonstrated to be linked with peripheral hypoxia, 64 and so it is conceivable that a CVE that impairs systemic perfusion may contribute to the development of RLS. Moreover, in the time sequence analysis reported by Szentkirályi et al., 53 VRFs such as obesity were found to be independently associated with incident RLS; however, when the analyses were conducted with reversed sequential order, RLS at baseline was not associated with incident CVE or with any VRF. Another (less likely) possibility is that positive associations reported in the literature between RLS and CVE may be due to older RLS-related treatment such as low-dose pergolide, which has been reported to give rise to valvular heart disease 65 ; of note, most studies did not report on RLS-related treatments such as dopamine agonists. Furthermore, most studies reviewed did not objectively measure markers of iron deficiency.
Consistent with its complex pathogenesis, it has been proposed that RLS may be divided into three discrete components: PLMS, subjective sensorimotor symptoms, and sleep disturbance 66 ; it is plausible that each component may contribute differently to vascular risk. Although PLMS occur frequently in RLS, they are not exclusively related to RLS and occur in a host of other sleep disorders and medical conditions. 8 We propose that, among patients with secondary forms of RLS, PLMS may serve as the physiological link to increased vascular risk. Numerous mechanisms may link PLMS with vascular disease. For example, PLMS are associated with surges of nocturnal sympathetic hyperactivity which manifest as transient elevations in night-time heart rate and blood pressure (BP). 14, 67 Recurrent surges in BP every night for many years or decades may cause repeated mechanical stress on the vasculature, leading to vascular remodeling; in addition, variability of blood flow caused by BP oscillations is thought to induce sheer stress, platelet activation, leading to atherosclerosis and a potentially hypercoagulable state. 68 Another mechanism that may link RLS with vascular disease is inflammation. In a study of patients with RLS, those with elevated PLM indices (≥45 PLMS per hour of sleep) had more than a 3-fold chance of having an elevated C-reactive protein (CRP), a marker of systemic inflammation, compared to RLS patients with lower PLM indices. In that study, the presence of RLS by itself was not reported to be associated with increased levels of serum CRP, suggesting that PLMS were the main modulator of the elevated CRP levels. 69 Indeed, prior work has suggested that RLS itself is not associated with elevated levels of inflammatory markers. 29, 70 These findings underscore the potential importance of PLMS, 71 rather than a diagnosis of RLS alone, in mediating inflammation as a possible linking mechanism.
Several limitations were present in the studies that investigated the prognostic value of PLMS, including the fact that these studies were limited by a lack of information about the presence of RLS at baseline and did not report on treatments for RLS/PLMS. Furthermore, arbitrary thresholds for PLMS severity do not have clear clinical significance or predictive value. Finally, a single measurement of PLMS at baseline does not account for the night-to-night variability and changes in PLMS seen over time. 72, 73 The inclusion of only peer-reviewed studies in our systematic review may have introduced a bias associated with exaggerating the estimate of the actual effect. 74 However, to mitigate the impact of a possible publication bias, we included studies published in open-access journals, which are presumably associated with less editorial bias against negative study results.
Future large population-based studies with long follow-up periods, a sufficient number of outcome events, a broad range of population demographic characteristics, and standardized definitions used to define PLMS/RLS (including primary vs. secondary forms, duration, and severity) are needed to explore further the potential prognostic role of RLS/PLMS in CVE development. Following this, randomized controlled trials would be needed to assess the impact of treating RLS/PLMS on vascular outcomes, with a particular emphasis on examining the potential role of severity and frequency of PLMS/RLS symptoms.
CONCLUSIONS
The available evidence on RLS as a prognostic factor for incident CVE and all-cause mortality was limited and inconclusive.
Significant heterogeneity in study populations, outcomes, and other methodological aspects introduced significant inconsistencies between studies. Duration, severity, and secondary versus primary RLS may be important features in understanding a possible relationship with CV disease and mortality. Although limited, the evidence on PLMS as a prognostic factor for incident CV diseases and mortality suggests a significant association.
